Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: blood pressure + drug + pressure  Related to the article below (Last Update: 8/5/2008)


eFluxMedia
UPDATE 1-Medicines Co gets FDA nod for blood pressure drug
Reuters - Aug 4, 2008
O: Quote, Profile, Research, Stock Buzz) said the US Food and Drug Administration approved its injectable blood pressure drug, Cleviprex, sending its shares ...
FDA approves Medicines Co.'s blood-pressure drug CNNMoney.com
Medicines Company wins approval for blood pressure drug Trading Markets (press release)
Injected Drug Approved for High Blood Pressure Forbes
dBTechno - HealthNews
all 42 news articles »  MDCO - OTC:CMTX
Novartis gets expanded blood-pressure drug OK
Forbes, NY - Aug 4, 2008
The drugs were already approved as secondary treatments. They are both once-daily tablets. High blood pressure affects about 73 million adult Americans and ...NVS
Children With Suspected High-Blood Pressure Need 24-Hour Checks
Bloomberg -
Continuous monitoring could also help evaluate the usefulness of blood- pressure drugs, the panel wrote. ``Accurate assessment and management'' of blood ...
Consumer Reports' Ratings of Blood Pressure Monitors and Blood ... eMediaWorld.com Newswire Press Release Distribution Service (press release)
all 12 news articles »  TYO:6645

Dividend.com
Novartis Can Relieve Investor Stress (NVS)
Dividend.com, NJ - Aug 4, 2008
... after the FDA (Food and Drug Administration) approved the drugs Diovan HCT and Exforge as initial treatments for high blood pressure. ...NVS

Dividend.com
Novartis AG (NYSE: NVS) NewsBite - NVS Hits 52-Week High
Market Intelligence Center, VA - Aug 4, 2008
Novartis announced this morning the Food and Drug Administration approved the drugs Diovan HCT and Exforge as initial treatments for high blood pressure. ...
Single-Pill Combinations Diovan HCT and Exforge Approved in US as ... SunHerald.com
all 35 news articles »  NVS - AG

Oneindia
A Daily Dose Of Garlic Can Help
Oneindia, India -
A daily dose of garlic can help in lowering blood pressure, says a new research. What's more, the magical plant can also be as effective as drugs, ...
Novartis reveals blood pressure drug approvals
Hays Pharma, UK - Aug 4, 2008
Novartis has revealed that two blood pressure medicines have been granted approval by the US Food and Drug Administration (FDA). ...NVS
US approves two Novartis blood pressure pills
Reuters - Aug 3, 2008
ZURICH, Aug 4 (Reuters) - US regulators have approved two single-pill high blood pressure drugs, Diovan HCT and Exforge, from Switzerland's Novartis AG ...NVS
Single-Pill Combinations Diovan HCT and Exforge Approved in US as ...
MarketWatch - Aug 3, 2008
In patients who are likely to need multiple drugs to achieve blood pressure goals, using single-pill combination medications first-line will help eliminate ...
FDA approves Novartis's combination medications for blood pressure ...
Trading Markets (press release), CA -
With the approvals, healthcare professionals are said to have have simplified treatment strategies to help control high blood pressure with Diovan HCT and ...NVS - OTC:CMTX
Source: Google News

Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: … -
R Collins, R Peto, S MacMahon, P Hebert, NH … - Lancet, 1990 - ncbi.nlm.nih.gov
... disease. Part 2, Short-term reductions in blood pressure: overview of randomised
drug trials in their epidemiological context. Collins ...

[PDF] Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of …
B Neal, S MacMahon, N Chapman? - Lancet, 2000 - dtu.ox.ac.uk
... trials comparing more intensive and less intensive blood-pressure-lowering strategies,
and trials comparing treatment regimens based on different drug classes. ...
-

… Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure -
AV Chobanian, GL Bakris, HR Black, WC Cushman, LA … - Hypertension, 2003 - Am Heart Assoc
... modifications to prevent the progressive rise in blood pressure and CVD; for
uncomplicated hypertension, thiazide diuretic should be used in drug treatment for ...

Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart … -
R Collins, S MacMahon - British Medical Bulletin, 1994 - British Council
... University Press. ARTICLE. Blood pressure, antihypertensive drug treatment and
the risks of stroke and of coronary heart disease. R Collins ...

… , insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal … -
EM Velazquez, S Mendoza, T Hamer, F Sosa, CJ … - Metabolism, 1994 - ncbi.nlm.nih.gov
... Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin
resistance, hyperandrogenemia, and systolic blood pressure, while facilitating ...

Do Nonsteroidal Anti-inflammatory Drugs Affect Blood Pressure? A Meta-Analysis -
AG Johnson, TV Nguyen, RO Day - Annals of Internal Medicine, 1994 - annals.highwire.org
... or treated with single doses of antihypertensive agents [23, 24], and in hypertensive
persons whose blood pressure had been controlled by drug therapy [21, 25 ...

Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an … -
DJ Webb, S Freestone, MJ Allen, GJ Muirhead - Am J Cardiol, 1999 - ncbi.nlm.nih.gov
... Agents/adverse effects; Antihypertensive Agents/pharmacology*; Blood
Pressure/drug effects; Cross-Over Studies; Double-Blind Method; ...

National High Blood Pressure Education Program Coordinating Committee
AV Chobanian, GL Bakris, HR Black, W Cushman, L … - … Evaluation, and Treatment of High Blood Pressure: the JNC-7 …, 2003 - Mass Med Soc
... evidence, but also specifically to simplify classification of blood-pressure levels
to ... modification for all patients with prehypertension and drug therapy only ...

Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive … -
JT Wright, Jr, G Bakris, T Greene, LY Agodoa, LJ … - JAMA, 2002 - Am Med Assoc
... percentage changes in the urine protein/creatinine ratio (geometric mean [SE]) from
baseline throughout follow-up by blood pressure and drug intervention. ...

Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 … -
MR Law, NJ Wald, JK Morris, RE Jordan - BMJ: British Medical Journal, 2003 - pubmedcentral.nih.gov
... Figure 1 shows the dose-response relations for the five categories of blood pressure
lowering drug for systolic pressure (the plots for diastolic pressure were ...

Source: Google Scholar

Blood Pressure Drug Telmisartan Shows Powerful Activity Against Stroke

 

Drug, Alone or in Combination, Eliminated Stroke Risk, Weill Cornell Team Reports

NEW YORK (Dec. 12, 2007) — Telmisartan, a drug widely used to help control blood pressure, may have uniquely potent activity in preventing stroke, according to a new study conducted in an animal model.

Whether they used the drug alone or in combination with a different type of antihypertensive medication, ramipril, Weill Cornell Medical College researchers found that rats fed a high-salt, stroke-inducing diet were completely protected from the brain attacks while on telmisartan.

"No other study has ever shown complete protection against stroke in this rat model using normal human drug doses" notes study senior author Dr. Daniel F. Catanzaro, professor of physiology and biophysics and professor of physiology in cardiothoracic surgery at Weill Cornell Medical College.

The study, which was funded by telmisartan's German maker, Boehringer Ingelheim Pharma GmbH & Co., is published online in the Journal of the American Society of Hypertension.

Telmisartan (brand name Micardis) is one of a class of widely used antihypertensive drugs known as angiotensin receptor blockers (ARBs). "These drugs primarily act on the vasculature to relax the small blood vessels," Dr. Catanzaro explains.
Telmisartan stands out from other ARBs in that its molecular structure allows it to more easily pass through the blood-brain barrier and enter the brain—something many drugs cannot do.

The new animal study was not constructed to specifically look at telmisartan's effect on stroke. "Because blood pressure is closely related to stroke risk, we really just wanted to look and see if combinations of antihypertensive drugs were better at lowering blood pressure and stroke compared to the use of single agents," Dr. Catanzaro explains.

In this case, his team tested two drugs—telmisartan and an ACE inhibitor, ramipril (Altace)—in a rat model long favored by stroke researchers. In this approach, rats are fed what's known as a "stroke-prone diet," meaning they get lots of salt in both their food and water.

"This rat model has been great at showing us the neuroprotective properties of different drugs in the past, and the results usually correlate with results in humans," Dr. Catanzaro says.

In the study, 25 rats were fed the stroke-prone diet for 8 weeks and received either no medication, telmisartan alone, ramipril alone, or the two drugs together at either full- or half-doses.

"A main finding was that combination therapy did reduce blood pressure the best of any treatment, and it also was best at cutting damage to the rats' hearts and kidneys," Dr. Catanzaro says. "But what was really surprising to us was that any regimen involving telmisartan at doses that would normally be given to humans completely prevented stroke in this model. Most studies with other drugs have used much higher doses and have found only partial protection."

Specifically, 83 percent of rats given no medication showed signs of stroke, as did 56 percent of rats given ramipril alone. However, no strokes were noted in the telmisartan-only or the telmisartan/ramipril combo groups.

Telmisartan's ability to easily pass through the blood-brain barrier (something ramipril cannot do) is likely behind the neuroprotective effect noted in the study, the researchers say.

"Going forward, that's something that we would really like to test out in head-to-head trials pitting telmisartan against other ARBs, for example," Dr. Catanzaro said. "At the same time, we'd like to examine whether telmisartan is actually getting into the brain, or if more peripheral effects—a lowering of blood pressure, for instance—are behind the reduction in stroke."

In the meantime, Boehringer Ingelheim is nearing the end of a major clinical trial looking at the effectiveness of combining telmisartan with ramipril to lower patients' blood pressures and reduce their odds for heart attack and stroke. Dr. Catanzaro's team is not involved in that study.

Co-authors on this study include lead researcher Dr. Ying Zhou, as well as Dr. Fangmin Yu and Dr. Ada R. Ene—all of Weill Cornell Medical College in New York City.


Weill Cornell Medical College


Weill Cornell Medical College—Cornell University's Medical School located in New York City—is committed to excellence in research, teaching, patient care and the advancement of the art and science of medicine, locally, nationally and globally. Weill Cornell, which is a principal academic affiliate of NewYork-Presbyterian Hospital, offers an innovative curriculum that integrates the teaching of basic and clinical sciences, problem-based learning, office-based preceptorships, and primary care and doctoring courses. Physicians and scientists of Weill Cornell Medical College are engaged in cutting-edge research in such areas as stem cells, genetics and gene therapy, geriatrics, neuroscience, structural biology, cardiovascular medicine, infectious disease, obesity, cancer, psychiatry and public health—and continue to delve ever deeper into the molecular basis of disease in an effort to unlock the mysteries behind the human body and the malfunctions that result in serious medical disorders. The Medical College—in its commitment to global health and education—has a strong presence in such places as Qatar, Tanzania, Haiti, Brazil, Austria and Turkey. With the historic Weill Cornell Medical College in Qatar, the Medical School is the first in the U.S. to offer its M.D. degree overseas. Weill Cornell is the birthplace of many medical advances—from the development of the Pap test for cervical cancer to the synthesis of penicillin, the first successful embryo-biopsy pregnancy and birth in the U.S., the first clinical trial for gene therapy for Parkinson's disease, the first indication of bone marrow's critical role in tumor growth, and, most recently, the world's first successful use of deep brain stimulation to treat a minimally-conscious brain-injured patient. For more information, visit www.med.cornell.edu.

Powered by Big Medium™

Contact Info
 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.